The Department of Paediatrics and Adolescent Medicine, the University Hospital Rigshospitalet, Copenhagen, Denmark.
Br J Haematol. 2012 Oct;159(1):18-27. doi: 10.1111/bjh.12016. Epub 2012 Aug 22.
l-asparaginase has been an element in the treatment for acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma since the late 1960s and remains an essential component of their combination chemotherapy. Among the major toxicities associated with l-asparaginase therapy are pancreatitis, allergic reactions, thrombotic events, hepatotoxicity and hyperlipidaemia. Acute pancreatitis is one of the most common reasons for stopping treatment with l-asparaginase. Short-term complications of asparaginase-associated pancreatitis include development of pseudocysts and pancreatic necrosis. Long-term complications include chronic pancreatitis and diabetes. The pathophysiology of asparaginase-associated pancreatitis remains to be uncovered. Individual clinical and genetic risk factors have been identified, but they are only weak predictors of pancreatitis. This review explores the definition, possible risk factors, treatment and complications of asparaginase-associated pancreatitis.
自 20 世纪 60 年代末以来，L-天冬酰胺酶一直是治疗急性淋巴细胞白血病（ALL）和非霍奇金淋巴瘤的一种元素，并且仍然是其联合化疗的重要组成部分。与 L-天冬酰胺酶治疗相关的主要毒性包括胰腺炎、过敏反应、血栓事件、肝毒性和高脂血症。急性胰腺炎是停止使用 L-天冬酰胺酶治疗的最常见原因之一。天冬酰胺酶相关胰腺炎的短期并发症包括假性囊肿和胰腺坏死的发展。长期并发症包括慢性胰腺炎和糖尿病。天冬酰胺酶相关胰腺炎的病理生理学仍有待揭示。已经确定了个体临床和遗传危险因素，但它们只是胰腺炎的弱预测因素。本综述探讨了天冬酰胺酶相关胰腺炎的定义、可能的危险因素、治疗和并发症。
